dalteparin has been researched along with Brain Neoplasms in 18 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adults with newly diagnosed malignant glioma were randomized to receive dalteparin 5000 anti-Xa units or placebo, both subcutaneously once daily for 6 months starting within 4 weeks of surgery." | 9.14 | PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. ( Agnelli, G; Baker, R; Falanga, A; Finch, T; Geerts, W; Julian, JA; Laperriere, NJ; Levine, MN; Malkin, MG; Parpia, S; Perry, JR; Rogers, LR; Sawaya, R, 2010) |
| " The aim of this study was to evaluate the correlation between pre-operative plasma levels of soluble fibrin polymers (SFP), as determined by a recently developed enzyme-linked immunosorbent assay (ELISA) assay (TpP), and the incidence of deep vein thrombosis (DVT) after elective neurosurgery." | 9.09 | Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. ( Agnelli, G; Baroni, M; D'Angelo, SV; Quintavalla, R; Severi, P; Sonaglia, F, 1999) |
| "Adults with newly diagnosed malignant glioma were randomized to receive dalteparin 5000 anti-Xa units or placebo, both subcutaneously once daily for 6 months starting within 4 weeks of surgery." | 5.14 | PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. ( Agnelli, G; Baker, R; Falanga, A; Finch, T; Geerts, W; Julian, JA; Laperriere, NJ; Levine, MN; Malkin, MG; Parpia, S; Perry, JR; Rogers, LR; Sawaya, R, 2010) |
| " The aim of this study was to evaluate the correlation between pre-operative plasma levels of soluble fibrin polymers (SFP), as determined by a recently developed enzyme-linked immunosorbent assay (ELISA) assay (TpP), and the incidence of deep vein thrombosis (DVT) after elective neurosurgery." | 5.09 | Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. ( Agnelli, G; Baroni, M; D'Angelo, SV; Quintavalla, R; Severi, P; Sonaglia, F, 1999) |
| " The initial treatment consisted of a 7-day course of subcutaneous dalteparin according to body weight." | 3.72 | Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. ( Jiménez, JA; Monreal, M; Roncales, J; Vilaseca, B; Zacharski, L, 2004) |
| "Spontaneous intracranial hemorrhage (ICH) is also a frequent occurrence in these patients, but there is limited data on the safety of therapeutic anticoagulation." | 1.46 | Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. ( Mantia, C; Neuberg, D; Puligandla, M; Uhlmann, EJ; Weber, GM; Zwicker, JI, 2017) |
| "BACKGROUND Intraoperative pulmonary embolism (PE) is a rare life-threatening complication in patients undergoing surgical intervention." | 1.43 | Successful Management of Intraoperative Acute Bilateral Pulmonary Embolism in a High Grade Astrocytoma Patient. ( Allouh, MZ; Hiasat, MY; Khraise, WN; Said, RS, 2016) |
| "To assess the risk for intracranial hemorrhage associated with the administration of therapeutic doses of low-molecular-weight heparin, we performed a matched, retrospective cohort study of 293 patients with cancer with brain metastases (104 with therapeutic enoxaparin and 189 controls)." | 1.42 | Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. ( Campigotto, F; Coletti, E; Donato, J; Neuberg, D; Uhlmann, EJ; Weber, GM; Zwicker, JI, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Pelargos, PE | 1 |
| Dunn, IF | 1 |
| Briggs, RG | 1 |
| Lin, YH | 1 |
| Dadario, NB | 1 |
| Young, IM | 1 |
| Conner, AK | 1 |
| Xu, W | 1 |
| Tanglay, O | 1 |
| Kim, SJ | 1 |
| Fonseka, RD | 1 |
| Bonney, PA | 1 |
| Chakraborty, AR | 1 |
| Nix, CE | 1 |
| Flecher, LR | 1 |
| Yeung, JT | 1 |
| Teo, C | 1 |
| Sughrue, ME | 1 |
| Mantia, C | 1 |
| Uhlmann, EJ | 2 |
| Puligandla, M | 1 |
| Weber, GM | 2 |
| Neuberg, D | 2 |
| Zwicker, JI | 2 |
| Donato, J | 1 |
| Campigotto, F | 1 |
| Coletti, E | 1 |
| Kreuziger, LB | 1 |
| Botros, MM | 1 |
| Mahmoud, MA | 1 |
| Costandi, AJ | 1 |
| Khraise, WN | 1 |
| Allouh, MZ | 1 |
| Hiasat, MY | 1 |
| Said, RS | 1 |
| Goldhaber, SZ | 1 |
| Dunn, K | 1 |
| Gerhard-Herman, M | 1 |
| Park, JK | 1 |
| Black, PM | 1 |
| Kaluza, V | 1 |
| Rao, DS | 1 |
| Said, JW | 1 |
| de Vos, S | 1 |
| Balzarotti, M | 1 |
| Fontana, F | 1 |
| Marras, C | 1 |
| Boiardi, A | 1 |
| Croci, D | 1 |
| Ciusani, E | 1 |
| Salmaggi, A | 1 |
| Eisenson, N | 1 |
| Dickinson, LD | 1 |
| Miller, LD | 1 |
| Patel, CP | 1 |
| Gupta, SK | 1 |
| Sonaglia, F | 1 |
| Agnelli, G | 2 |
| Baroni, M | 1 |
| Severi, P | 1 |
| Quintavalla, R | 1 |
| D'Angelo, SV | 1 |
| Kleindienst, A | 1 |
| Harvey, HB | 1 |
| Mater, E | 1 |
| Bronst, J | 1 |
| Flack, J | 1 |
| Herenz, K | 1 |
| Haupt, WF | 1 |
| Schön, R | 1 |
| Perry, JR | 1 |
| Julian, JA | 1 |
| Laperriere, NJ | 1 |
| Geerts, W | 1 |
| Rogers, LR | 1 |
| Malkin, MG | 1 |
| Sawaya, R | 1 |
| Baker, R | 1 |
| Falanga, A | 1 |
| Parpia, S | 1 |
| Finch, T | 1 |
| Levine, MN | 1 |
| Monreal, M | 1 |
| Zacharski, L | 1 |
| Jiménez, JA | 1 |
| Roncales, J | 1 |
| Vilaseca, B | 1 |
| Robins, HI | 1 |
| O'Neill, A | 1 |
| Gilbert, M | 1 |
| Olsen, M | 1 |
| Sapiente, R | 1 |
| Berkey, B | 1 |
| Mehta, M | 1 |
| Perry, SL | 1 |
| Bohlin, C | 1 |
| Reardon, DA | 1 |
| Desjardins, A | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Vredenburgh, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Evaluate the Effect of Dalteparin and Radiation Therapy on Survival Compared to the RTOG RPA Database and on Thromboembolic Events in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00028678] | Phase 2 | 45 participants (Actual) | Interventional | 2002-07-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for dalteparin and Brain Neoplasms
| Article | Year |
|---|---|
Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis.
Topics: Bandages; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Double-Blind Method; Enoxaparin; F | 2002 |
Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors.
Topics: Adult; Aged; Anticoagulants; Brain Neoplasms; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Male; | 1998 |
Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery.
Topics: Adult; Aged; Biomarkers; Brain Neoplasms; Elective Surgical Procedures; Enoxaparin; Female; Fibrin; | 1999 |
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Neoplasms; Dalteparin; Factor Xa; Female; Glio | 2010 |
Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.
Topics: Adult; Aged; Anticoagulants; Brain Neoplasms; Combined Modality Therapy; Dalteparin; Disease-Free Su | 2008 |
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
Topics: Adult; Aged; Brain Neoplasms; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S | 2009 |
12 other studies available for dalteparin and Brain Neoplasms
| Article | Year |
|---|---|
Venous Thromboembolism Prophylaxis: Safe, but Still Provocative?
Topics: Anticoagulants; Brain Neoplasms; Craniotomy; Enoxaparin; Humans; Postoperative Complications; Precis | 2019 |
Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience.
Topics: Adult; Anticoagulants; Brain Neoplasms; Craniotomy; Enoxaparin; Female; Humans; Male; Middle Aged; R | 2021 |
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Neoplasms; Cohort Studies; Enoxaparin; Female; | 2017 |
Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Boston; Brain Neoplasms; Case-Control Studies; Enoxa | 2015 |
Balancing bleeding in brain metastases.
Topics: Anticoagulants; Brain Neoplasms; Enoxaparin; Female; Humans; Intracranial Hemorrhages; Male; Neoplas | 2015 |
Reliable low-molecular-weight heparin reversal in a child undergoing emergency surgery: a case report.
Topics: Anticoagulants; Blood Loss, Surgical; Brain Neoplasms; Decompressive Craniectomy; Emergency Medical | 2016 |
Successful Management of Intraoperative Acute Bilateral Pulmonary Embolism in a High Grade Astrocytoma Patient.
Topics: Adult; Anticoagulants; Astrocytoma; Brain Neoplasms; Enoxaparin; Female; Humans; Intraoperative Comp | 2016 |
Primary extranodal nasal-type natural killer/T-cell lymphoma of the brain: a case report.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; CD3 Complex; CD56 Antigen; DNA, Neoplasm; Enoxapar | 2006 |
In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.
Topics: Adolescent; Adult; Aged; Apoptosis; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, | 2006 |
Management of thrombosis in a neuro-oncology patient.
Topics: Adult; Anticoagulants; Astrocytoma; Brain Neoplasms; Enoxaparin; Humans; Injections, Subcutaneous; L | 2007 |
Early antithrombotic prophylaxis with low molecular weight heparin in neurosurgery.
Topics: Adult; Aged; Aged, 80 and over; Brain Injuries; Brain Neoplasms; Cerebrospinal Fluid Shunts; Contrai | 2003 |
Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Body Weight; Brain Neoplasms; Cohor | 2004 |